Conference Description:

Hear from and meet with the leading figures in precision oncology to explore how companies are innovating in precision medicine, digital pathology and molecular testing to accelerate timelines and reduce risk in drug development, with in-depth consideration of the latest multiplexed and cytometry tools impacting biomarker research & validation.

Expand your knowledge & discuss future priorities in:
- Molecular Analysis, Multi-Cancer Early Detection and Testing, Companion Diagnostic Development
- Biomarkers for Clinical Development and Personalised Patient Treatment
& much more!



Meet Key Decision makers representing large pharma & biotech companies:
- Anna Maria Lara Coenan-Stass - Associate Director, Clinical Biomarkers & Companion Diagnoistics at Merck KGaA
- Twan Lammers - Head of Department, Nanomedicine and Theranostics at Aachen University
- Kjetil Tasken - Head, Institute for Cancer Research, Group Leader, ICR Dept of Cancer Immunology
& many more!

View the agenda here - https://www.oxfordglobal.co.uk/precision -oncology/agenda/download-agenda/?utm_so urce=wcc&utm_medium=eventlisting&utm_cam paign=biomarkers&utm_content=preonc2023< br />
Co-located with Biomarkers Europe 2023 and Targets and Cell Types 2023, attendees will receive access to all three events. For more information contact [email protected]